Take this medicine4-5hoursbefore taking these medicines, as they may inhibit the intestinal absorption of levothyroxine sodium.
What else you should know if you take Solsint with other medicines:
If you need to have aradiological examinationor any otherdiagnostic testthat usescontrast media, inform your doctor that you are taking this medicine, as they may inject a substance that may affect thyroid function.
Solsint with food and drinks
Inform your doctor if you consume soy products, especially if you modify the proportion of soy products in your diet. Soy products may reduce the intestinal absorption of levothyroxine, so you may need to adjust your dose of this medicine.
Pregnancy and breastfeeding
Consult your doctor or pharmacist before taking any medicine.
Pregnancy
Breastfeeding
Driving and operating machinery
There is no evidence to suggest that this medicine affects your ability to drive and operate machinery, as levothyroxine is identical to the naturally produced thyroid hormone.
This medicine contains less than 23 mg of sodium (1 mmol) per 1 ml of oral solution; this is, essentially "sodium-free".
Follow exactly the administration instructions of this medication as indicated by your doctor. If in doubt, consult your doctor or pharmacist again.
Your doctor will determine your individual dose based on the exams and laboratory tests that have been performed on you.
Dose:
For individual treatment, Solsint single-dose vials are available in different doses of 13-200 micrograms of levothyroxine sodium. In most cases, only one single-dose vial will be taken per day.
Adults:
– Treatment for hypothyroidism:
Adult patients will start with 25-50 micrograms of levothyroxine sodium per day. This dose will be increased following the doctor's instructions in 25-50 micrograms of levothyroxine sodium at intervals of 2 to 4 weeks, until reaching a daily dose of 100-200 micrograms of levothyroxine sodium (equivalent to 1-2 single-dose vials of Solsint).
– Prevention of recurrence of goiter after surgical removal and treatment of benign goiter: The daily dose is 75-200 micrograms of levothyroxine sodium.
− Concurrent therapy during antithyroid treatment of hyperthyroidism: The daily dose is 50-100 micrograms of levothyroxine sodium.
– After thyroid surgery to remove a malignant tumor of the thyroid gland: The daily dose is 150-300 micrograms of levothyroxine.
– For diagnostic use in thyroid suppression test: The daily dose is 200 micrograms of levothyroxine sodium for the 14 days prior to the radiological examination (scintigraphy).
Older adults, patients with coronary disease, and patients with severe or chronic hypothyroidism:
Treatment with thyroid hormones will be started with special caution. This means that initially a lower dose will be administered, which will be gradually increased at longer intervals with frequent monitoring by laboratory tests.
Children:
The dose in children depends on the child's age, weight, and the condition to be treated. The doctor will monitor the treatment of your child to ensure that they take the correct dose.
Consult your doctor or pharmacist if you believe the effects of this medication are too intense or too weak.
Administration form:
Administration of Solsint with dilution or mixing:
Administration of Solsint directly into the mouth or with a spoon:
Discard the empty vial.
Treatment duration:
You should take this medication for the time indicated by your doctor.
If you take more Solsint than you should
If you ingest a higher dose than prescribed, you may experience symptoms of hyperthyroidism, such as palpitations, anxiety, agitation, excessive sweating, or tremors (see section "4. Possible adverse effects"). Contact your doctor if these effects occur.
If you forget to take Solsint
If you forget to take a dose, do not take it when you remember and continue taking your regular daily dose the next day.
If you interrupt treatment with Solsint
To be successful, you must take the prescribed dose of Solsint regularly. Do not change, suspend, or interrupt treatment without consulting your doctor. Symptoms may reappear if you suspend or interrupt treatment.
If you have any other doubts about the use of this medication, consult your doctor or pharmacist.
Like all medications, Solsint may produce adverse effects, although not all people will experience them.
The risk of experiencingadverse effectsis insignificant if you follow the instructions and undergo the laboratory tests prescribed by your doctor, since levothyroxine, the active principle of this medication, is equivalent to the natural thyroid hormone.
The following adverse effects occur with an unknown frequency: angioedema, skin rash, urticaria.
In case of hypersensitivity, allergic reactions may affect the skin and respiratory tract.Contact your doctor immediatelyif you observe these effects.
If you take more Solsint than prescribed or do not tolerate the intensity of the dose(for example, if the dose is too high for your needs), you may experience typical symptoms of hyperthyroidism, such as:
– weight loss and increased appetite;
– tremors, agitation, difficulty sleeping, headache, increased intracranial pressure with swelling of theeyes (especially in children);
– palpitations, cardiac rhythm disorders, especially tachycardia, chest pain with a feeling of constriction (angina pectoris);
– high blood pressure;
− vomiting, diarrhea;
– muscle weakness and muscle cramps;
– irregular menstruation;
– excessive sweating, hair loss, sensation of burning (face redness), fever.
Consult your doctor if you observe any of these effects.Your doctor will decide whether to interrupt treatment for several days or reduce the dose until the adverse effects have disappeared.
Reporting Adverse Effects
If you experience adverse effects, consult your doctor or pharmacist, even if they do not appear in this prospectus. You can also report them directly through theSpanish System for Pharmacovigilance of Medicines for Human Use:https://www.notificaRAM.es.By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not store at a temperature above 25°C.
Store in the original packaging to protect it from light.
After opening the first packet: use the single-dose containers within the next 15días.
After opening a single-dose container or after diluting its contents: use immediately.
Do not use this medication after the expiration date shown on the label after CAD. The expiration date is the last day of the month indicated.
Medicines should not be disposed of through drains or in the trash. Dispose of the containers and medicines you no longer need at the SIGREpoint of your pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medicines you no longer need. By doing so, you will help protect the environment.
The active principle is levothyroxine sodium.
1 ml of oral solution of Solsint 13 micrograms contains 13 micrograms of levothyroxine sodium.
1 ml of oral solution of Solsint 25 micrograms contains 25 micrograms of levothyroxine sodium.
1 ml of oral solution of Solsint 50 micrograms contains 50 micrograms of levothyroxine sodium.
1 ml of oral solution of Solsint 75 micrograms contains 75 micrograms of levothyroxine sodium.
1 ml of oral solution of Solsint 88 micrograms contains 88 micrograms of levothyroxine sodium.
1ml of oral solution of Solsint 100 micrograms contains 100 micrograms of levothyroxine sodium.
1 ml of oral solution of Solsint 112 micrograms contains 112 micrograms of levothyroxine sodium.
1 ml of oral solution of Solsint 125 micrograms contains 125 micrograms of levothyroxine sodium.
1 ml of oral solution of Solsint 137 micrograms contains 137 micrograms of levothyroxine sodium.
1 ml of oral solution of Solsint 150 micrograms contains 150 micrograms of levothyroxine sodium.
1 ml of oral solution of Solsint 175 micrograms contains 175 micrograms of levothyroxine sodium.
1 ml of oral solution of Solsint 200 micrograms contains 200 micrograms of levothyroxine sodium.
The other component is glycerol 85%.
Appearance of the product and contents of the package
Clear and colorless solution that tends to slightly yellow, supplied in a single-dose container of 1ml of white non-transparent color. Each single-dose container has a label with a color indicating the concentration of the dose and the name of the product (Solsint).
Concentration [micrograms] | Color |
13 | Green |
25 | Orange |
50 | White |
75 | Blue |
88 | Olive |
100 | Yellow |
112 | Pink |
125 | Brown |
137 | Turquoise |
150 | Blue |
175 | Purple |
200 | Pink |
This medicine is supplied in blister packs of polyethylene terephthalate/aluminum/polyethylene (PET/Alu/PE) with 5 single-dose containers each.
This medicine is available in formats of 30single-dose containers of 1ml.
Only some sizes of packaging may be marketed.
Marketing authorization holder and responsible manufacturer
IBSA Farmaceutici Italia Srl
Via Martiri di Cefalonia, 2,
26900 Lodi
Italy
For more information about this medicine, please contact the local representative of the marketing authorization holder:
Instituto Bioquimico Iberico IBSA S.L.
Avenida Diagonal 605,
Planta 8, Local 1,
08028 Barcelona (Spain)
This medicine is authorized in the member states of the European Economic Area with the following names:
Germany, Netherlands, Poland: Tirosint SOL Austria: Syntroxine SOL
Denmark, Norway, Sweden, Slovakia: Tirosintsol Spain: Solsint
Greece: Tirosol
Hungary, Czech Republic: Synotirex Italy: Levotirsol
Last review date of this leaflet: February 2023
For detailed information about this medicine, please visit the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es)
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.